Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial

Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-HPV type at first vaccination (baseline) remains unc...

Full description

Bibliographic Details
Main Authors: Shangying Hu, Xiaoqian Xu, Fengcai Zhu, Ying Hong, Yuemei Hu, Xun Zhang, Qinjing Pan, Wenhua Zhang, Chengfu Zhang, Xiaoping Yang, Jiaxi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Shuang Zhao, Naveen Karkada, Haiwen Tang, Dan Bi, Frank Struyf, Fanghui Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2021-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
human papillomavirus
clinical trial
cervical cancer
china
efficacy
prevention
vaccines
infection
Online Access:http://dx.doi.org/10.1080/21645515.2020.1829411

Internet

http://dx.doi.org/10.1080/21645515.2020.1829411

Similar Items